Compare Glenmark Pharma with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs UNICHEM LAB - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA UNICHEM LAB GLENMARK PHARMA/
UNICHEM LAB
 
P/E (TTM) x 12.3 -98.6 - View Chart
P/BV x 1.8 0.5 324.5% View Chart
Dividend Yield % 0.6 2.6 22.4%  

Financials

 GLENMARK PHARMA   UNICHEM LAB
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
UNICHEM LAB
Mar-19
GLENMARK PHARMA/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs712292 243.7%   
Low Rs484182 265.7%   
Sales per share (Unadj.) Rs349.6167.7 208.5%  
Earnings per share (Unadj.) Rs32.8-3.6 -902.9%  
Cash flow per share (Unadj.) Rs44.35.9 746.1%  
Dividends per share (Unadj.) Rs2.004.00 50.0%  
Dividend yield (eoy) %0.31.7 19.8%  
Book value per share (Unadj.) Rs198.6372.3 53.4%  
Shares outstanding (eoy) m282.1770.38 400.9%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.71.4 120.9%   
Avg P/E ratio x18.2-65.3 -27.9%  
P/CF ratio (eoy) x13.539.9 33.8%  
Price / Book Value ratio x3.00.6 472.5%  
Dividend payout %6.1-110.2 -5.5%   
Avg Mkt Cap Rs m168,62516,680 1,010.9%   
No. of employees `00012.02.6 462.6%   
Total wages/salary Rs m20,5612,393 859.1%   
Avg. sales/employee Rs Th8,196.04,535.2 180.7%   
Avg. wages/employee Rs Th1,708.1919.8 185.7%   
Avg. net profit/employee Rs Th768.5-98.2 -782.5%   
INCOME DATA
Net Sales Rs m98,65511,801 836.0%  
Other income Rs m2,081984 211.5%   
Total revenues Rs m100,73612,785 787.9%   
Gross profit Rs m15,858-835 -1,899.4%  
Depreciation Rs m3,259674 483.8%   
Interest Rs m3,34675 4,449.3%   
Profit before tax Rs m11,335-600 -1,890.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m1,6720-   
Tax Rs m3,756-343 -1,093.7%   
Profit after tax Rs m9,250-256 -3,619.9%  
Gross profit margin %16.1-7.1 -227.2%  
Effective tax rate %33.157.3 57.9%   
Net profit margin %9.4-2.2 -433.0%  
BALANCE SHEET DATA
Current assets Rs m66,96820,384 328.5%   
Current liabilities Rs m40,2115,029 799.6%   
Net working cap to sales %27.1130.1 20.8%  
Current ratio x1.74.1 41.1%  
Inventory Days Days83105 79.5%  
Debtors Days Days81135 60.2%  
Net fixed assets Rs m33,3229,023 369.3%   
Share capital Rs m282141 200.4%   
"Free" reserves Rs m55,77026,058 214.0%   
Net worth Rs m56,05226,199 213.9%   
Long term debt Rs m35,7380-   
Total assets Rs m132,88831,496 421.9%  
Interest coverage x4.4-7.0 -62.9%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.70.4 198.1%   
Return on assets %9.5-0.6 -1,655.5%  
Return on equity %16.5-1.0 -1,692.0%  
Return on capital %17.8-2.0 -891.1%  
Exports to sales %069.4 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA8,188 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m62,9988,188 769.4%   
Fx outflow Rs m22,859596 3,835.3%   
Net fx Rs m40,1407,592 528.7%   
CASH FLOW
From Operations Rs m13,242-3,278 -404.0%  
From Investments Rs m-6,990-2,860 244.4%  
From Financial Activity Rs m-7,387-24 30,526.4%  
Net Cashflow Rs m-2,971-4,690 63.3%  

Share Holding

Indian Promoters % 48.3 50.1 96.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 15.1 45.7%  
FIIs % 34.4 3.0 1,146.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 31.7 33.1%  
Shareholders   56,727 20,176 281.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   ALKEM LABORATORIES  FRESENIUS KABI ONCO.  FDC LTD.  TORRENT PHARMA  STRIDES PHARMA SCIENCE  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 186 Points Higher; Energy and Power Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day on a positive note.

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

UNICHEM LAB Announces Quarterly Results (1QFY20); Net Profit Up 102.2% (Quarterly Result Update)

Jul 30, 2019 | Updated on Jul 30, 2019

For the quarter ended June 2019, UNICHEM LAB has posted a net profit of Rs 5 m (up 102.2% YoY). Sales on the other hand came in at Rs 2 bn (up 15.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB 2018-19 Annual Report Analysis (Annual Result Update)

Jul 4, 2019 | Updated on Jul 4, 2019

Here's an analysis of the annual report of UNICHEM LAB for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of UNICHEM LAB. Also includes updates on the valuation of UNICHEM LAB.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Nov 19, 2019 03:37 PM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS